Two pioneers in MS nursing have joined the list of Canadian recipients of the Giants of MS award, presented by the Consortium of MS Centers (CMSC). Read More
Neurology
Geographic determinants of health: location, location
June 3, 2024Geography has a significant impact on MS patients’ access to care and treatment options, according to data presented at the Consortium of MS Centers (CMSC) 38th annual meeting, held May 29-June 1 in Nashville, Tennessee. Read More
New guidance on use of sNfL in practice
May 27, 2024An international panel of experts in conjunction with the Consortium of MS Centers (CMSC) has developed recommendations on the use of neurofilament-light chain (NfL) as a biomarker of disease activity in multiple sclerosis (Freedman et al. eBioMedicine 2024;101:104970). Read More
New developments in epilepsy: focus on cenobamate
May 2, 2024Cenobamate received Health Canada authorization last year as adjunctive therapy for patients with partial-onset seizures who are not adequately controlled with conventional therapies. The drug acts as a sodium channel blocker through selection inhibition of the persistent sodium current, and as a GABAA receptor modulator. Read More
Treatment initiation with a higher-efficacy DMT: update from AAN
April 25, 2024Focus on ofatumumab
There is a growing body of evidence supporting the use of high-efficacy disease-modifying therapies (DMT) as first-line agents in the treatment of multiple sclerosis. Since the TRANSFORMS trial over a decade ago, numerous pivotal trials have demonstrated the superiority of higher-efficacy DMTs over lower-efficacy agents (Cohen et al. N Engl J Med 2010;362:402-415). The concern with this more aggressive approach was safety. However, the accumulation of long-term safety data, most notably for anti-CD20 agents, has demonstrated the low risk of serious adverse events with sustained exposure to selected high-efficacy DMTs in clinical practice. Read More